The most common genetic alteration identi®ed in transitional cell carcinoma (TCC) of the bladder is loss of heterozygosity (LOH) on chromosome 9. However, localization of tumor suppressor genes on 9q has been hampered by the low frequency of subchromosomal deletions. We have analysed 139 primary, initial low stage TCC of the bladder using a panel of 28 microsatellite markers spanning chromosome 9 at an average distance of 5 Mb, following a primer-extension preampli®cation (PEP) technique. Sixty-seven (48%) tumors showed LOH at one or more loci and partial deletions were detected in 62 (45%) tumors; apparent monosomy 9 was detected in only ®ve (4%) tumors. Deletions were more frequent on 9q (44%) than on 9p (23%), the latter being mostly associated with 9q deletion, suggesting that alteration of genes on 9q may be an early event associated with super®cial papillary tumors. Combined data from the cases with partial 9q deletions displayed four candidate regions for tumor suppressor loci, based on the frequency of deletion observed and tumors with unique deletions at these sites. In two tumors, the unique partial deletion comprised D9S12 at 9q22.3, a region encompassing loci for the Gorlin syndrome and multiple self-healing squamous epithelioma gene. In two other tumors, the single LOH was identi®ed at the D9S172 locus at 9q31-32 where the dysautonia and Fukuyama-type congenital muscular dystrophy genes have been located. One tumor showed unique LOH at the GSN locus at 9q33, a region frequently deleted in other sporadic tumors while the fourth region of deletion was observed at 9q34 between ASS and ABL-1, in two tumors. This region is frequently deleted in tumors and encompasses the locus for the hereditary hemorrhagic telangiectasia gene. These ®ndings suggest four target regions on 9q within which suppressor genes for TCC may reside.
Introduction
Previous cytogenetic and molecular genetic studies have revealed various chromosomal anomalies in human transitional cell carcinoma (TCC) of the bladder. Loss of heterozygosity (LOH) on chromosome 9 is the most frequent genetic alteration identi®ed in bladder tumors and is present in all stages and grades; approximately 60 ± 70% of bladder tumors show LOH of at least one locus on either arm of this chromosome Stadler et al., 1994; Simoneau et al., 1996) , thus suggesting that loss of one or more suppressor gene(s) on chromosome 9 may be an early or initiating event in bladder tumorigenesis. Earlier attempts to localize a common region of deletion have shown a high frequency of apparent monosomy 9, the majority of tumors having LOH at all informative loci (Cairns et al., 1993; Miyao et al., 1993; Habuchi et al., 1995) . Re®nements in localization of candidate tumor suppressor loci has been hampered by the low frequency of partial deletions. Nevertheless, LOH studies have identi®ed some tumors with subchromosomal deletions that provided evidence for the presence of at least two tumor suppressor genes on chromosome 9; one or more on 9p, with other genes possibly located on 9q (Ruppert et al., 1993; Cairns et al., 1994; Keen and Knowles, 1994; Orlow et al., 1994; Habuchi et al., 1995) . On 9p, the minimal region of deletion has been mapped to a 2-cM region between the markers IFNA and D9S171 at 9p21 (Devlin et al., 1994; Stadler et al., 1994) ; this region, also deleted in several other types of tumors includes the recently identi®ed tumor suppressor gene p16 (also known as CDKN2, INK4A or MTS1). The location of other putative tumor suppressor gene(s) on the q arm is less certain; all deletions on 9q were large with a common region of deletion between 9q13-21.1 (D9S15) and 9q33-34.1 (D9S60) (Cairns et al., 1993; Linnenbach et al., 1993; Keen and Knowles, 1994; Habuchi et al., 1995) . Evidence for two tumor suppressor loci on 9q has been described by Simoneau et al., (1996) and Habuchi et al., (1995) : both studies report a distal region of deletion at 9q33-9q34 and a large proximal region spanning either 9p12 to 9q21 or 9q13 to 9q31.
Most studies reporting on chromosome 9 deletions have been performed on heterogeneous bladder cancer specimen where higher stage and recurrent tumors may be over represented. We hypothesized that low stage tumors found at ®rst diagnosis may be genetically more stable and allow easier identi®cation of subchromosomal deletions associated with early bladder carcinogenesis. In the present study, a detailed LOH analysis was performed using microsatellite markers spanning chromosome 9 on 139 primary TCC, all ®rst tumors of low stage Ta or T1. The results showed a low frequency of apparent monosomy 9 and subchromo-somal deletions that were more frequent on 9q than on 9p. Moreover, the analysis identi®ed four candidate regions on 9q for putative tumor suppressor loci.
Results
In order to maximize the use of tumor DNA, we have adapted the technique of whole genome ampli®cation to the study of genetic alterations in bladder cancer. Using this technique, also known as primer-extension preampli®cation (PEP) it is estimated that almost 80% of a cell genome is ampli®ed to a minimum of 30 copies (Zhang et al., 1992) . This has allowed us to investigate multiple genetic loci with as little as 10 ng of tumor genomic DNA. The quality of the ampli®ed DNA was ascertained using as second round of ampli®cation after PEP, PCR ampli®cation conditions for ras or p53 exons routinely done in our laboratory (data not shown). Besides reducing the quantity of DNA needed for the study, the PEP step often reduced the background of non-speci®c bands observed on the autoradiogram (data not shown). Moreover, for all markers, microsatellite patterns obtained with and without PEP were ®rst compared using DNA from cell lines and were identical except for the decrease in background (data not shown).
The results obtained from the 139 cases of initial primary TCC analysed for loss of heterozygosity of chromosome 9 are summarized in Table 1 . The mean number of NI (not informative i.e. homozygous) marker per individual was 28% which corresponds to our genotyping experience in French-Canadians. Each patient was informative (i.e. heterozygous) at several loci and LOH was de®ned as a reduction (450%) in intensity of signal (as interpreted by NIH Image analysis) or absence of signal from the PCR product of one allele in the tumor (observed in more than 90% of LOH). Examples of LOH are shown in Figure 1 . Overall, 52% (72 of 139) of the tumors retained all informative markers on both chromosome arms. Only ®ve tumors (4%) showed LOH of all informative markers examined, suggesting apparent monosomy 9, while 62 (45%) tumors showed partial deletions. These comprised six (4%) tumors with LOH on 9p only, 35 (25%) tumors with LOH on 9q only and 21 (15%) tumors with LOH on both arms of the chromosome. In four patients the tumor corresponding to the ®rst recurrence was also analysed and the patterns of LOH of the initial tumor and ®rst recurrence were identical (data not shown); two of them had deletions only on 9q while one presented an apparent monosomy and the fourth one had no sign of LOH at all informative markers. No correlation was found between chromosome 9 loss as detected by LOH and tumor stage. LOH of at least one locus on chromosome 9 was observed in 51 of 110 Ta TCCs (46%) and 13 of 25 T1 TCCs (52%). A correlation was found between the presence of LOH on chromosome 9 and tumor grade (w 2 =8.58, P=0.013); LOH was found in 14 of 45 grade 1 TCCs (31%), 46 of 79 grade 2 TCCs (58%) and seven of 13 grade 3 TCCs (54%). Figure 2 illustrates the distribution of LOH for each marker analysed along chromosome 9. It shows that the percentage of LOH varies considerably between the 9p and 9q markers and the preponderance of 9q LOH in our tumor population. The 9q arm was divided in ®ve regions (A to E) corresponding to peaks of deletion frequencies. The pattern of LOH in 48 of the 62 tumors with partial deletions is illustrated in Figure 3 . Eight of the 21 tumors involving deletions on both the short and long arm of the chromosome showed a clear region of retention of heterozygosity near the centromeric region (Figure 3a, tumors 33, 42, 46, 49, 52, 91, 93) . These data suggest the existence of at least 2 target regions on the chromosome, one on 9p and one on 9q. Of the six tumors that had deletions on 9p only, ®ve had telomeric deletions with a common region of deletion observed between IFNA and D9S126 loci (Figure 3b, tumors 47, 61, 65, 110 and 156) .
Deletions observed on 9q were larger, covering the region between D9S15 (9q13-q21.1) and D9S67 (9q34.1-tr). Of the 35 tumors that had deletions of 9q only, only 6 had lost the entire chromosome arm (data Figure 2 , one common area of loss involved marker D9S15 (region A) which is located at 9q13-21.1 (Povey et al., 1992) . This locus, D9S15, showed LOH in a high proportion of tumors analysed but it is dicult to know its importance as it was always accompanied by more distal LOH or as in tumor 84 (Figure 3c) , it was part of a large non informative region.
Marker D9S12 at 9q22.3 was also frequently deleted and is part of region B, encompassing markers D9S201 to D9S180 (Figure 2) . In one case, tumor 154, only the D9S12 locus was deleted indicating the minimal target region ( Figure 3c) ; moreover tumors 52 and 148 (Figure 3a,c) , although presenting LOH at other loci, showed a deletion at D9S12 with a clear region of retention on either side of this locus. Region C encompasses markers D9S176 to D9S172 (Figure 2 ), where these three markers are often deleted in our tumor population. Three tumors had a single LOH in region C: tumor 77 at D9S53, tumor 89 and tumor 139 at D9S172; although presenting more than one deletion, tumor 148 also showed a LOH at D9S53 with a clear region of retention on each side (Figure 3a ,c) as well as tumors 12, 19, 71 and 144 who showed LOH at D9S172 (Figure 3a ). These observations suggest that the minimal region of deletion in region C 9q22.3 ± 31 is comprised between D9S53 and D9S58 (9q22.331). Marker D9S154, which is proximal to GSN at 9q32-33 was part of our fourth area of deletion, region D encompassing markers HXB to D9S260 (Figure 2) . In a majority of tumors presenting LOH in region D, other regions of 9q arm were also involved excluding tumor 120 and 122 which had a single LOH at HXB and GSN respectively (Figure 3c ). Three tumors, 108, 111 and 136 also presented a single LOH in region D at D9S260 locus with a common region of deletion limited by marker GSN (9q33) and D9S61 (9q33-34.1) (Figure 3c ). Therefore a minimal region of deletion for these tumors was de®ned between GSN and D9S260. Region E, a distal region at 9q33-34, encompasses markers ASS to ABL-1 and is frequently involved as an area of deletion in our tumor population ( Figure  2 ). Marker D9S61 clearly separated regions D and E since many tumors with deletions both in region D and E retain this marker (Figure 3a, tumors 1 , 14, 23, 42; c, tumors 53, 74, 84, 148) . Tumor 63 had only the ASS locus deleted, while tumor 104 showed also a deletion at this locus in addition to more centromeric deletions. Moreover, two tumors, 84 and 143, presented a similar pattern of deletion as tumor 104 with only a small deletion in region E at locus D9S113. Tumor 5 had only the telomeric locus D9S67 deleted (Figure 3c ).
Discussion
One of the most striking results of this analysis is the high proportion of subchromosomal deletions observed in our samples. Overall, 49% (68 of 139) of the tumors showed LOH for at least one informative locus of which only ®ve tumors showed LOH at all informative markers, suggesting a monosomy 9. These results are at variance with most previous studies reporting apparent monosomy usually at much higher frequency and subchromosomal deletions in less than 20 ± 30% of cases (Cairns et al., 1993; Ruppert et al., 1993; Keen and Knowles, 1994; Knowles et al., 1994; Simoneau et al., 1996) . However, recently Van Tilborg et al., (1998) observed only one apparent monosomy in 40 tumors analysed (2,5%) and subchromosomal deletions in 23 tumors (58%), thus supporting our observation. The higher percentage of partial deletions reported herein may be due to the number of markers analysed along the chromosome, but more likely re¯ects the tumor population studied which was comprised essentially of Ta/T1 ®rst TCCs with a majority of Ta tumors (*80%). This group of tumors is more homogeneous than in most studies and corresponds to very early tumors, thus possibly allowing the identi®cation of early events in bladder tumorigenesis.
It is interesting to note the presence of many deleted regions in the tumors studied in spite of the early stage of these tumors thus supporting the hypothesis of more than one tumor suppressor gene on chromosome 9. Deletions on 9q were much more frequent than on 9p; 35 tumors (25%) had deletions on 9q only compared to only six tumors (4%) with deletions on 9p alone. In more than 75% of the cases, deletions on 9p were concomitant with large 9q deletions. Furthermore, deletions of 9p were observed in 33% of tumors 43 cm, compared to 17% of tumors of smaller size (data not shown, P=0.038). These observations suggest that deletions of genes on 9q may be an earlier event associated with super®cial papillary tumors.
As shown by previous reports, we also identi®ed a common region of deletion on 9p21 between the markers IFNA and D9S126 Devlin et al., 1994) . This region of 9p is also deleted in many other types of cancer including melanoma , glioma (Olopade et al., 1992) , leukemia (Diaz et al., 1990 ) and non small cell lung cancer (Merlo et al., 1994) . The p16 tumor suppressor gene, which is a negative regulator of cyclin-dependent kinase 4 is localized within this region (Nobori et al., 1994) . Another tumor suppressor gene, p15 (also described as INK4B or MTS2), has been also identi®ed in this region and deletions of this gene occur frequently in cancer cell lines and in certain malignancies (Kamb et al., 1994; Shapiro and Rollins, 1996) .
In the present study, even though deletions involving 9q often covered a very large region of the chromosome, this chromosome arm was divided in ®ve regions showing higher frequencies of LOH. The ®rst region de®ned by marker D9S15, close to the centromere, was never the only deleted region in the tumors analysed in the present study. It is thus dicult to assess its importance in bladder tumorigenesis. The four other regions, in addition to being frequently deleted, have more potential to harbor tumor suppressor loci since unique LOH are found at these sites in a few tumors. The region of D9S12 at 9q22.3 (B) was deleted in 35% of informative cases and was the unique LOH in two tumors (102, 154) . Many genes associated to diseases have been mapped to this region of the chromosome including NBCCS (nevoid basal cell carcinoma syndrome or Gorlin Syndrome), ESS1 (multiple self healing squamous epithelioma or Ferguson ± Smith Syndrome), FACC (Fanconi anae-mia complementation group C), XPAC (xeroderma pigmentosum complementation group A), HSN1 (hereditary sensory neuropathy type 1) and CKS2 (cyclin dependent kinases regulatory subunit 2) (Povey et al., 1994 . All six genes are located within the interval D9S12 and D9S180 and could thus be considered as candidate tumor suppressor genes in bladder cancer. Simoneau et al., (1996) excluded the 9q22.3 region based on the LOH data of only one tumor and on lack of mutation in the NBCCS gene in 20 primary bladder tumors screened by SSCP. Further analysis of this region is needed to clarify the situation.
The region of D9S172 at 9q31-32 is the second region where the presence of a putative tumor suppressor locus for bladder cancer is considered (region C). Two tumors (89 and 139) have only the D9S172 locus deleted while four tumors (12, 19, 71 and 144) with deletions in other regions presented a deletion at this locus surrounded by regions of retention. A few genes have been mapped in this region but only the dysautonia gene (DYS) and the Fukuyama-type congenital muscular dystrophy gene (FCMD) seem candidate tumor suppressor genes. The DYS gene has been narrowed to the region between D9S310 and D9S261, a small region between D9S172 and D9S58 (Pericak-Vance et al., 1995) while the FCMD gene has been mapped to an approximately 3 cM interval between D9S306 (identical to D9S53) and D9S172 (Miyake et al., 1997) . Further investigation of this region will be necessary to clarify whether a putative tumor suppressor locus is located proximally or distally to D9S172.
The region between GSN and D9S260 at 9q33 was the unique LOH in two tumors (111, 122) (region D). The gelsolin gene, which encodes an actin-regulatory protein, is localized in 9q33 at this locus. Gelsolin expression was found to be undetectable or extremely low in human bladder cancer cell lines and tissues compared to its expression in normal bladder epithelial cells suggesting that gelsolin may have a role as tumor suppressor in human bladder carcinogenesis (Tanaka et al., 1995) . Recently, Habuchi et al., (1997) identi®ed a novel candidate tumor suppressor locus at 9q32-33 at the D9S195 locus which is distal to D9S154 and proximal to GSN. This tumor suppressor locus was not restricted to bladder cancer since deletions in this region were also reported in oesophagal, ovarian, renal and head and neck cancers (Habuchi et al., 1997) .
In the distal region of 9q, deletions were telomeric to D9S61 at 9q33-34.1. Two tumors (84 and 143) showed LOH at D9S113 with retention of adjoining markers. Within this region several genes have been mapped, including the ABO gene-encoded glycosyltransferase (Meldgaard et al., 1995) , the tuberous sclerosis gene (TSC1), the nail-patella syndrome 1 (NPS1) (Povey et al., 1994) , the torsion dystonia gene (DYT1) (Ozelius et al., 1997) , the collagen type V a1 chain (COL5A1) (Northrup et al., 1994) and the hereditary hemorrhagic telangiectasia gene (HHT) . The TSC1 (Hornigold et al., 1997; van Slegtenhorst et al., 1997) and ABO loci are located distal to the ASS locus and should be excluded on the basis of tumor 63 which had only the ASS locus deleted (Figure 4c, tumor 63) . On the other hand the HHT gene has been mapped between D9S61 and D9S63 on 9q33-34 and could be a tumor suppressor gene responsible for an antiangiogenesis factor (McDonald et al., 1994) . Patient 63 showed retention at D9S260 and D9S61 and LOH at ASS. The genetic distance between these latter markers is estimated to be 2 Mb, suggesting that the candidate gene may be located between D9S61 and ASS. Recently, Simoneau et al., (1996) have reported tumors with deletion at marker D9S63 and also proposed that HHT could be a tumor suppressor gene candidate in bladder cancer.
There is growing evidence that several genes on chromosome 9 are involved in bladder cancer. Keen and Knowles (1994) have reported the possibility of two target loci on 9p, and the same group (Habuchi et al., 1995) reported two tumor suppressor loci on 9q as did Simoneau et al., (1996) , but their proximal locus was slightly dierent. Our results indicate the existence of at least ®ve possible tumor suppressor loci involving chromosome 9: three of them, at 9p21, 9q33 and 9q34, having been previously reported and two promising ones at 9q22.3 and 9q31. The large proportion of LOH we observed in the 9q22.3 and 9q31 regions may be due to the homogeneity of our material. Primary low stage tumors may represent an ideal material to pinpoint early genetic events as larger chromosomal deletions may occur upon cancer recurrence and progression. Despite many reports on chromosome 9 LOH in bladder cancer, it is still not clear which arm (9p or 9q) is ®rst altered in tumorigenesis. We observed that 9q is deleted more frequently than 9p in Ta/T1 tumors and that 9p losses rarely occur in the absence of 9q deletions thus supporting the hypothesis that inactivation of one or more genes located on 9q is an early event in bladder tumorigenesis (Dalbagni et al., 1993; Orlow et al., 1994; Simoneau et al., 1996) .
Materials and methods

Tissues and DNA extraction
Bladder tumors (139) were obtained by transurethral resection, embedded in OCT (optimal cutting temperature compound, Tissue Tek, Miles, McLean, VA) and stored at 7808C. Of these, 110 were stage Ta, 25, stage T1 and four unde®ned Ta or T1; 45 were grade 1, 79 grade 2 and 13 grade 3. No patient had pure carcinoma in situ (TIS) as it was an exclusion criteria to the study (Allard et al., 1995) but three had Ta or T1 tumors in a background of TIS. A blood sample from each patient was collected in EDTA tubes and stored at 7808C. Tumor DNA was extracted by proteinase K digestion from frozen 20-mm tissue sections or cell suspension as previously described (LaRue et al., 1995) . DNA from blood leukocytes was prepared from 200 ml whole blood using also proteinase K digestion (Rousseau et al., 1994) . DNA concentrations were determined by the¯uorometric diaminobenzoic acid assay (DABA).
PEP (primer-extension preampli®cation)
Prior to microsatellite analyses of chromosome 9, a preampli®cation step was carried out as described by Zhang et al., (1992) . Brie¯y, 10 ng of genomic DNA was ampli®ed in 10 mM Tris-HCl pH 8.3, 2.5 mM MgCl 2 100 mg/ml gelatin, 100 mM of each dNTP, 33 mM 15-mer random primers (SP180 random primers, Operon Technologies, Alameda, CA, USA) and 5 U Taq DNA polymerase (Gibco ± BRL, Mississauga, Ontario, Canada) in a total volume of 60 ml. Fifty cycles consisting of 1 min at 928C, 2 min at 378C, a ramping step of 10 s/8C up to 558C and a 4 min elongation at 558C were carried out in a Perkin Elmer Cetus DNA thermal cycler. Aliquots from each reaction were then used as template DNA for microsatellite analysis.
Microsatellite analysis
The 28 microsatellite markers used to screen chromosome 9 are listed in the LDB database (http://cedar.genetics.soton.ac.uk/public_html) and in Figure 3 and are separated by an average distance of 5 Mb. Microsatellite ampli®cation was carried out as described by Keen and Knowles (1994) . For each PCR reaction the forward primer was end-labeled with g 32 P-ATP (NEN Life Science products, Boston, MA, USA) using T4 polynucleotide kinase (Gibco ± BRL). PCR ampli®cation was carried out in a volume of 12.5 ml using 3 ml of the PEP reaction in 20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.25 ± 2.5 mM MgCl 2 (depending on the primers used), 200 mM of each dNTP, and containing 2 pmol of each primer (MapPairs, Research Genetics, Huntsville, AL, USA) and 1 U of Taq DNA polymerase. Ampli®cation consisted of 27 cycles of 1 min at 958C, 1 min at 558C and 1.5 min at 728C. For D9S55, D9S180 and D9S12 annealing temperature was 528C, 588C and 618C respectively while markers D9S149, D9S66 and D9S154 annealing temperature was 578C and ampli®cation was set to 30 cycles. Take note that samples that failed to amplify using the PEP step were ampli®ed de novo using 5 ng of genomic DNA. Ten ml of loading buer (95% formamide, 10 mM EDTA, 0.3% xylene cyanol, 0.3% bromophenol blue) was added to each reaction and following denaturation at 808C for 6 min, 3 ml aliquots were electrophoresed through a denaturing 6% acrylamide-8.3 M urea gel. Gels were dried and exposed to X-ray ®lms for 2 ± 18 h. Assessment of microsatellite patterns was made initially by visual inspection. In the 10% of cases where partial deletions were observed, the autoradiograms were scanned and images analysed by NIH Image software version 1.6.
